AstraZeneca, Ranbaxy Can't Ax Claims In Nexium Antitrust MDL

Law360, Los Angeles (November 27, 2013, 10:13 PM ET) -- A Massachusetts federal judge on Wednesday rejected AstraZeneca PLC and Ranbaxy Inc.'s bid to dismiss as time-barred certain claims in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca’s heartburn drug Nexium.

U.S. District Judge William G. Young denied AstraZeneca and generics manufacturer Ranbaxy's motion for partial summary judgment on claims relating to Ranbaxy's alleged exclusion from the market because of a settlement agreement between the two companies, saying the plaintiffs have presented evidence supporting their...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required

Case Information

Case Title

In Re: Nexium (Esomeprazole) Antitrust Litigation

Case Number

1:12-md-02409

Court

Massachusetts

Nature of Suit

Anti-Trust

Judge

William G. Young

Law360 Coverage

Date Filed

December 7, 2012

Sections

Law Firms Mentioned

Companies Mentioned

Related Articles